Intelligence Feed event · Policy · 2026-09-24

    Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress

    Question

    Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress

    Direct answer

    Hutchmed will present detailed clinical results from two pivotal Phase III trials at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid. The studies evaluate savolitinib in combination with AstraZeneca's osimertinib for patients with MET-amplified non-small cell lung cancer. Both the global SAFFRON trial and the China-based SANOVO trial achieved statistically significant improvements in efficacy endpoints, paving the way for expanded global regulatory submissions.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-24
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress”, revision 1, evidence through 2026-09-24. https://marketontology.com/market-events/2026-09-24/hutchmed-to-present-phase-iii-savolitinib-nsclc-trial-results-at-esmo-2026-congr-3f5ecf

    POLICY
    Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress
    Hutchmed will present detailed clinical results from two pivotal Phase III trials at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid. The studies evaluate savolitinib in combination with AstraZeneca's osimertinib for patients with MET-amplified non-small cell lung cancer. Both the global SAFFRON trial and the China-based SANOVO trial achieved statistically significant improvements in efficacy endpoints, paving the way for expanded global regulatory submissions.
    HCMAZN
    Impact
    60
    SEP 24
    SIG
    88%
    HCMAZN
    Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress
    Hutchmed will present detailed clinical results from two pivotal Phase III trials at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid. The studies evaluate savolitinib in combination with AstraZeneca's osimertinib for patients with MET-amplified non-small cell lung cancer. Both the global SAFFRON trial and the China-based SANOVO trial achieved statistically significant improvements in efficacy endpoints, paving the way for expanded global regulatory submissions.
    → Positive Phase III trial readouts for the savolitinib-osimertinib combination support supplemental regulatory filings and commercial milestone recognition for HCM and AZN.
    Impact
    Hutchmed will present detailed clinical results from two pivotal Phase III trials at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid. The studies evaluate savolitinib in combination with AstraZeneca's osimertinib for patients with MET-amplified non-small cell lung cancer. Both the global SAFFRON trial and the China-based SANOVO trial achieved statistically significant improvements in efficacy endpoints, paving the way for expanded global regulatory submissions.
    Affected
    HCMAZN
    Transmission
    Positive Phase III trial readouts for the savolitinib-osimertinib combination support supplemental regulatory filings and commercial milestone recognition for HCM and AZN.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMpipeline de-risking and potential regulatory filing milestonesUp1-4wSource explicitly reports statistically significant Phase III SAFFRON and SANOVO results.
    AZNoncology franchise lifecycle extension with osimertinib combination therapiesUp1-4wOsimertinib is co-evaluated in the reported SAFFRON and SANOVO trials.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed13.90 2026-09-24+0.29%+4.82%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month